Dupont Capital Management Corp Has $5.86 Million Holdings in Boston Scientific Co. (BSX)

Dupont Capital Management Corp cut its position in shares of Boston Scientific Co. (NYSE:BSX) by 9.1% in the third quarter, HoldingsChannel reports. The institutional investor owned 152,137 shares of the medical equipment provider’s stock after selling 15,175 shares during the period. Dupont Capital Management Corp’s holdings in Boston Scientific were worth $5,857,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of the business. IMA Wealth Inc. lifted its stake in Boston Scientific by 1.1% during the third quarter. IMA Wealth Inc. now owns 117,815 shares of the medical equipment provider’s stock valued at $4,536,000 after buying an additional 1,330 shares in the last quarter. Synovus Financial Corp lifted its stake in Boston Scientific by 37.2% during the third quarter. Synovus Financial Corp now owns 5,000 shares of the medical equipment provider’s stock valued at $191,000 after buying an additional 1,356 shares in the last quarter. First American Trust FSB lifted its stake in Boston Scientific by 1.3% during the third quarter. First American Trust FSB now owns 113,375 shares of the medical equipment provider’s stock valued at $4,365,000 after buying an additional 1,470 shares in the last quarter. Cubist Systematic Strategies LLC lifted its stake in Boston Scientific by 3.1% during the second quarter. Cubist Systematic Strategies LLC now owns 51,105 shares of the medical equipment provider’s stock valued at $1,671,000 after buying an additional 1,547 shares in the last quarter. Finally, Oppenheimer Asset Management Inc. lifted its stake in Boston Scientific by 4.0% during the third quarter. Oppenheimer Asset Management Inc. now owns 39,979 shares of the medical equipment provider’s stock valued at $1,537,000 after buying an additional 1,555 shares in the last quarter. 91.24% of the stock is owned by institutional investors.

A number of analysts have commented on BSX shares. Raymond James upped their price objective on shares of Boston Scientific from $40.00 to $41.00 and gave the company a “strong-buy” rating in a research note on Tuesday, September 4th. Piper Jaffray Companies increased their price target on shares of Boston Scientific to $38.00 and gave the stock an “overweight” rating in a research report on Thursday, July 26th. Jefferies Financial Group raised shares of Boston Scientific from a “hold” rating to a “buy” rating and increased their price target for the stock from $34.00 to $42.00 in a research report on Tuesday, September 4th. Morgan Stanley increased their price target on shares of Boston Scientific from $33.00 to $38.00 and gave the stock an “overweight” rating in a research report on Thursday, July 26th. Finally, Barclays initiated coverage on shares of Boston Scientific in a research report on Monday, October 15th. They issued an “overweight” rating and a $43.00 price target for the company. One analyst has rated the stock with a sell rating, two have issued a hold rating, nineteen have issued a buy rating and three have assigned a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $39.00.

NYSE BSX opened at $38.60 on Friday. The company has a market capitalization of $52.52 billion, a PE ratio of 26.54, a P/E/G ratio of 2.49 and a beta of 0.68. The company has a quick ratio of 0.56, a current ratio of 0.78 and a debt-to-equity ratio of 0.58. Boston Scientific Co. has a 52-week low of $24.54 and a 52-week high of $39.44.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, October 24th. The medical equipment provider reported $0.35 earnings per share for the quarter, beating the consensus estimate of $0.34 by $0.01. The firm had revenue of $2.39 billion for the quarter, compared to analyst estimates of $2.40 billion. Boston Scientific had a net margin of 6.93% and a return on equity of 26.44%. The company’s revenue for the quarter was up 7.7% on a year-over-year basis. During the same quarter last year, the firm earned $0.31 earnings per share. Sell-side analysts predict that Boston Scientific Co. will post 1.39 EPS for the current fiscal year.

In related news, EVP David A. Pierce sold 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 4th. The shares were sold at an average price of $36.02, for a total transaction of $180,100.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Chairman Michael F. Mahoney sold 116,666 shares of the firm’s stock in a transaction that occurred on Monday, September 10th. The shares were sold at an average price of $35.88, for a total transaction of $4,185,976.08. Following the transaction, the chairman now directly owns 2,023,104 shares in the company, valued at approximately $72,588,971.52. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 414,000 shares of company stock worth $15,347,937. Insiders own 0.73% of the company’s stock.

WARNING: “Dupont Capital Management Corp Has $5.86 Million Holdings in Boston Scientific Co. (BSX)” was first reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this article on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this article can be viewed at https://www.thelincolnianonline.com/2018/11/10/dupont-capital-management-corp-has-5-86-million-holdings-in-boston-scientific-co-bsx.html.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.

Recommended Story: How does inflation affect different investments?

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Co. (NYSE:BSX).

Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply